Q-omics provides the consensus-scored ZNF28 profile across patient tissues and cancer cell-line models. ZNF28 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF28 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ZNF28 RNA expression shows 21,105 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where ZNF28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF28 survival associations across molecular data types. ZNF28 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF28 RNA expression–survival associations across cancer types. High ZNF28 expression shows unfavorable associations in LGG, MESO, LUSC and LIHC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF28 RNA expression.
This table summarizes ZNF28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF28 shows higher tumor expression in BLCA, STAD, LIHC, LUAD, BRCA and UCEC. The BLCA box plot shows higher ZNF28 RNA expression in tumor versus normal tissue (log2 FC = +1.531, t-test p < 0.001).
This table shows molecular features associated with ZNF28 in patient tissues and cancer cell lines. In patient samples, ZNF28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
